Labrado explained that Biomodulin T is a biological immunomodulator composed of fractions of bovine thymus, produced by BioCen in injectable form, and mainly indicated for immunological dysfunction.
The director highlighted its use in the treatment of cellular immunodeficiency, with proven results in the prevention of recurrent respiratory infections in the elderly (60 years and older), during a conversation in this capital arrangedd by Caribbean Pharmaceutical Company.
Likewise, he noted, clinical studies show its safety in thymic hypoplasia in children, as a complementary therapy in oncology patients during or after chemo/radiotherapy and in the prevention of Covid-19 in older adults, among other uses.
Questioned by Prensa Latina about the results of its use in nursing homes in Cuba during Covid-19, Labrado highlighted the notable reduction of lethality in this population group.
In this regard, he pointed out that a study showed its effectiveness in the prevention of respiratory infections six months after discontinuing the treatment.
Another outcome of Cuban biotechnology is Biotrofer, an anti-anemia and nutritional supplement of natural origin, also obtained at BioCen, a national reference institution, he added.
The expert commented that Biotrofer incorporates iron in people, with almost zero side effects, treats anemia in pregnant women, children and older adults, and improves the results of high-performance athletes.
His lecture motivated a considerable group of questions from doctors and health technicians gathered in the Oceania room of the Crowne Plaza hotel.
BioCen has several plants, including the active ingredient plant where the compound for the production of Biomodulin T is obtained; the institution is distinguished by its good pharmaceutical production practices and its quality control system.